Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

Rare Guillain-Barré Syndrome cases were found after ChAdOx1 vaccine in India; vigilance is urged despite vaccine’s overall safety.

Efgartigimod alfa is under clinical development by Argenx and currently in Phase II for Guillain-Barre Syndrome.

Peter and Zechariah Mehler have drawn kudos from Jews who favor an aggressive response to anti-Israel protests.

Read about vaccine sales, Akums and more in the latest Market Talks covering Health Care.